Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Class A Ordinary Shares, nominal value $0.000273235 per share
-
Shares outstanding
-
45,164,898
-
Total 13F shares
-
40,790,628
-
Share change
-
+811,784
-
Total reported value
-
$1,583,711,476
-
Put/Call ratio
-
16%
-
Price per share
-
$38.83
-
Number of holders
-
200
-
Value change
-
+$42,923,169
-
Number of buys
-
105
-
Number of sells
-
100
Institutional Holders of Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares, nominal value $0.000273235 per share (KNSA) as of Q3 2025
As of 30 Sep 2025,
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares, nominal value $0.000273235 per share (KNSA) was held by
200 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,790,628 shares.
The largest 10 holders included
Rubric Capital Management LP, VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, Fairmount Funds Management LLC, ACADIAN ASSET MANAGEMENT LLC, MORGAN STANLEY, D. E. Shaw & Co., Inc., ARROWSTREET CAPITAL, LIMITED PARTNERSHIP, and MILLENNIUM MANAGEMENT LLC.
This page lists
200
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.